Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy
{"title":"转移性前列腺癌的治疗。","authors":"Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy","doi":"10.1159/000546930","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.</p><p><strong>Summary: </strong>We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.</p><p><strong>Key messages: </strong>The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"1-12"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Management of Metastatic Prostate Cancer.\",\"authors\":\"Gunhild von Amsberg, Tobias Busenbender, Anja Coym, Moritz Kaune, Nadja Strewinsky, Jonas Ekrutt, Derya Tilki, Sergey Dyshlovoy\",\"doi\":\"10.1159/000546930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.</p><p><strong>Summary: </strong>We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.</p><p><strong>Key messages: </strong>The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.</p>\",\"PeriodicalId\":19543,\"journal\":{\"name\":\"Oncology Research and Treatment\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology Research and Treatment\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000546930\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Background: Advanced stages of prostate cancer (PCa), in particular metastatic castration-resistant prostate cancer, are associated with significant morbidity and mortality. The androgen receptor (AR) signaling pathway is a cornerstone of therapeutic intervention, but resistance mechanisms and disease progression demand increasingly complex treatment strategies.
Summary: We provide a comprehensive overview on the management of metastatic PCa, highlighting the evolution of treatment approaches and their clinical implications. Androgen deprivation therapy remains the backbone of therapy, enhanced by androgen synthesis inhibitors, AR inhibitors, and emerging AR degraders. Taxane-based chemotherapy, radiopharmaceuticals like radium-223 and lutetium-177 PSMA-617, and PARP inhibitors have expanded the therapeutic arsenal. Novel treatment approaches are in preclinical and clinical development. Various factors must be taken into account when deciding on the optimal treatment strategy including disease and patient-specific aspects. In addition, previous treatment lines may impact the efficacy of subsequent therapeutic approaches.
Key messages: The growing number of treatment options and a better understanding of the biological processes involved in tumor progression and the development of resistance are enabling increasingly individualized treatment of patients with advanced PCa.
期刊介绍:
With the first issue in 2014, the journal ''Onkologie'' has changed its title to ''Oncology Research and Treatment''. By this change, publisher and editor set the scene for the further development of this interdisciplinary journal. The English title makes it clear that the articles are published in English – a logical step for the journal, which is listed in all relevant international databases. For excellent manuscripts, a ''Fast Track'' was introduced: The review is carried out within 2 weeks; after acceptance the papers are published online within 14 days and immediately released as ''Editor’s Choice'' to provide the authors with maximum visibility of their results. Interesting case reports are published in the section ''Novel Insights from Clinical Practice'' which clearly highlights the scientific advances which the report presents.